http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 23 Feb 2026 06:46:46 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Accendra+Health+Inc+%28ACH%29+PT+Lowered+to+%243+at+UBS/26038959.html <p>UBS analyst Kevin Caliendo lowered the price target on Accendra Health Inc (NYSE: ACH) to $3.00 (from $4.00) while maintaining a Neutral rating.</p><p>The analyst comments "As a follow-up to our initial take on 4Q results and guide (link), we make multiple adjustments to our forecast (detailed below). 4Q EBITDA was relatively in-line with our estimates. The midpoints of 2026 EBITDA and FCF guidance however came in slightly below our/ estimates. With the P&HS sale behind them, management begins 2026 with a tighter focus on improving the underlying business, making the right investments in technology, improving collection rates and most importantly, http://www.streetinsider.com/Analyst+PT+Change/Accendra+Health+Inc+%28ACH%29+PT+Lowered+to+%243+at+UBS/26038959.html Mon, 23 Feb 2026 06:46:46 -0500 ACH http://www.streetinsider.com/Analyst+Comments/Accendra+Health+Inc+%28ACH%29+PT+Lowered+to+%243+at+UBS/26038959.html <p>UBS analyst Kevin Caliendo lowered the price target on Accendra Health Inc (NYSE: ACH) to $3.00 (from $4.00) while maintaining a Neutral rating.</p><p>The analyst comments "As a follow-up to our initial take on 4Q results and guide (link), we make multiple adjustments to our forecast (detailed below). 4Q EBITDA was relatively in-line with our estimates. The midpoints of 2026 EBITDA and FCF guidance however came in slightly below our/ estimates. With the P&HS sale behind them, management begins 2026 with a tighter focus on improving the underlying business, making the right investments in technology, improving collection rates and most importantly, http://www.streetinsider.com/Analyst+Comments/Accendra+Health+Inc+%28ACH%29+PT+Lowered+to+%243+at+UBS/26038959.html Mon, 23 Feb 2026 06:46:46 -0500 ACH http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++ACCENDRA+HEALTH+INCVA+++For%3A+Dec+31/26036360.html si-local-file:///var/storage/secattach/20260220/26036360.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++ACCENDRA+HEALTH+INCVA+++For%3A+Dec+31/26036360.html Fri, 20 Feb 2026 16:20:00 -0500 ACH O.00177991 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++ACCENDRA+HEALTH+INCVA+++For%3A+Dec+31/26036360.html si-local-file:///var/storage/secattach/20260220/26036360.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++ACCENDRA+HEALTH+INCVA+++For%3A+Dec+31/26036360.html Fri, 20 Feb 2026 16:20:00 -0500 ACH O.00177991 http://www.streetinsider.com/Analyst+PT+Change/Aluminum+Corporation+Of+China+%28ACH%29+PT+Lowered+to+%242.25+at+BofA+Securities/26032702.html BofA Securities analyst Allen Lutz lowered the price target on Aluminum Corporation Of China (NYSE: ACH) to $2.25 (from $2.50) while maintaining a Underperform rating. http://www.streetinsider.com/Analyst+PT+Change/Aluminum+Corporation+Of+China+%28ACH%29+PT+Lowered+to+%242.25+at+BofA+Securities/26032702.html Fri, 20 Feb 2026 06:36:36 -0500 ACH http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ACCENDRA+HEALTH+INCVA+++For%3A+Feb+19/26029905.html si-local-file:///var/storage/secattach/20260219/26029905.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ACCENDRA+HEALTH+INCVA+++For%3A+Feb+19/26029905.html Thu, 19 Feb 2026 16:10:00 -0500 ACH O.00177991 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ACCENDRA+HEALTH+INCVA+++For%3A+Feb+19/26029905.html si-local-file:///var/storage/secattach/20260219/26029905.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ACCENDRA+HEALTH+INCVA+++For%3A+Feb+19/26029905.html Thu, 19 Feb 2026 16:10:00 -0500 ACH O.00177991 http://www.streetinsider.com/Earnings/Accendra+Health%2C+Inc.+%28ACH%29+Misses+Q4+EPS+by+1c+%3B+Offers+Guidance/26029772.html <p>Accendra Health, Inc. (NYSE: ACH) reported Q4 EPS of $0.21, $0.01 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $709 million versus the consensus estimate of $713.43 million.</p><p><strong>GUIDANCE:</strong></p><p>Accendra Health, Inc. sees FY2026 revenue of $2.55-2.65 billion, versus the consensus of $2.6 billion.</p><p>For earnings history and earnings-related data on Accendra Health, Inc. (ACH) <a href="http://www.streetinsider.com/ec_earnings.php?q=ACH">click here</a>.</p> http://www.streetinsider.com/Earnings/Accendra+Health%2C+Inc.+%28ACH%29+Misses+Q4+EPS+by+1c+%3B+Offers+Guidance/26029772.html Thu, 19 Feb 2026 16:07:34 -0500 ACH http://www.streetinsider.com/Guidance/Accendra+Health%2C+Inc.+%28ACH%29+Misses+Q4+EPS+by+1c+%3B+Offers+Guidance/26029772.html <p>Accendra Health, Inc. (NYSE: ACH) reported Q4 EPS of $0.21, $0.01 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $709 million versus the consensus estimate of $713.43 million.</p><p><strong>GUIDANCE:</strong></p><p>Accendra Health, Inc. sees FY2026 revenue of $2.55-2.65 billion, versus the consensus of $2.6 billion.</p><p>For earnings history and earnings-related data on Accendra Health, Inc. (ACH) <a href="http://www.streetinsider.com/ec_earnings.php?q=ACH">click here</a>.</p> http://www.streetinsider.com/Guidance/Accendra+Health%2C+Inc.+%28ACH%29+Misses+Q4+EPS+by+1c+%3B+Offers+Guidance/26029772.html Thu, 19 Feb 2026 16:07:34 -0500 ACH http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Press+Releases/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html <p class="bwalignc"> <i>Completed Sale of Products &amp; Healthcare Services Business On December 31, 2025</i> </p><p class="bwalignc"> <i>Strong Cash Flow and Debt Reduction In Quarter</i> </p> <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. </p><p> “We ended the fourth quarter with the completion of the sale of the Products &amp; Healthcare Services (P&amp;HS) business on December 31, 2025, and we are extremely excited to embark on the next http://www.streetinsider.com/Business+Wire/Accendra+Health+Reports+Fourth+Quarter+2025+Financial+Results/26029663.html Thu, 19 Feb 2026 16:05:00 -0500 A.12225836 ACH O.00177991 O.17227147 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ACCENDRA+HEALTH+INCVA++++++++++++++++Filed+by%3A+CHARLES+SCHWAB+INVESTMENT+MANAGEMENT+INC/25991924.html si-local-file:///var/storage/secattach/20260212/25991924.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ACCENDRA+HEALTH+INCVA++++++++++++++++Filed+by%3A+CHARLES+SCHWAB+INVESTMENT+MANAGEMENT+INC/25991924.html Thu, 12 Feb 2026 16:11:00 -0500 ACH O.00177991 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ACCENDRA+HEALTH+INCVA++++++++++++++++Filed+by%3A+CHARLES+SCHWAB+INVESTMENT+MANAGEMENT+INC/25991924.html si-local-file:///var/storage/secattach/20260212/25991924.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++ACCENDRA+HEALTH+INCVA++++++++++++++++Filed+by%3A+CHARLES+SCHWAB+INVESTMENT+MANAGEMENT+INC/25991924.html Thu, 12 Feb 2026 16:11:00 -0500 ACH O.00177991 http://www.streetinsider.com/Press+Releases/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. </p><p> The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. </p><p> All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the http://www.streetinsider.com/Press+Releases/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html Thu, 05 Feb 2026 16:05:00 -0500 ACH O.00177991 http://www.streetinsider.com/Press+Releases/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. </p><p> The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. </p><p> All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the http://www.streetinsider.com/Press+Releases/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html Thu, 05 Feb 2026 16:05:00 -0500 ACH O.00177991 http://www.streetinsider.com/Business+Wire/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. </p><p> The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. </p><p> All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the http://www.streetinsider.com/Business+Wire/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html Thu, 05 Feb 2026 16:05:00 -0500 ACH O.00177991 http://www.streetinsider.com/Business+Wire/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html <p> RICHMOND, Va.--(BUSINESS WIRE)-- Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange. </p><p> The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. </p><p> All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the http://www.streetinsider.com/Business+Wire/Accendra+Health+Announces+Fourth+Quarter+2025+Earnings+Release+Date+and+Conference+Call/25954683.html Thu, 05 Feb 2026 16:05:00 -0500 ACH O.00177991 http://www.streetinsider.com/Intl+Ratings/Aluminum+Corporation+Of+China+Ltd+%282600%3AHK%29+%28ACH%29+PT+Raised+to+HK%2416+at+JPMorgan/25839570.html JPMorgan analyst Avery Chan raised the price target on Aluminum Corporation Of China Ltd (2600:HK) (NYSE: ACH) to HK$16.00 (from HK$12.50) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Aluminum+Corporation+Of+China+Ltd+%282600%3AHK%29+%28ACH%29+PT+Raised+to+HK%2416+at+JPMorgan/25839570.html Tue, 13 Jan 2026 03:58:32 -0500 ACH http://www.streetinsider.com/Intl+Ratings/Aluminum+Corporation+Of+China+Ltd+%282600%3AHK%29+%28ACH%29+PT+Raised+to+HK%2416+at+JPMorgan/25839570.html JPMorgan analyst Avery Chan raised the price target on Aluminum Corporation Of China Ltd (2600:HK) (NYSE: ACH) to HK$16.00 (from HK$12.50) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Aluminum+Corporation+Of+China+Ltd+%282600%3AHK%29+%28ACH%29+PT+Raised+to+HK%2416+at+JPMorgan/25839570.html Tue, 13 Jan 2026 03:58:32 -0500 ACH